An Open-Label, Sequential, Ascending Single-Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of an Intravenous Infusion of SEL-037 in Subjects With Elevated Blood Uric Acid Levels

Trial Profile

An Open-Label, Sequential, Ascending Single-Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of an Intravenous Infusion of SEL-037 in Subjects With Elevated Blood Uric Acid Levels

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Pegadricase (Primary)
  • Indications Gout; Tumour lysis syndrome
  • Focus Adverse reactions; Proof of concept
  • Sponsors 3SBio
  • Most Recent Events

    • 19 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 15 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016.
    • 01 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top